Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
Ethiopia is taking significant steps to address the rising prevalence rate of diabetes, a condition that poses a growing public health challenge in the country. Following the increasing prevalence of ...